Optimer Posts Wider Loss - Analyst Blog NASDAQ The company initiated a phase IIIb study evaluating the prophylactic use of Dificid in patients undergoing bone marrow transplantation (BMT) or hematopoietic stem cell transplant (HSCT). Optimer also plans to initiate another study on Dificid ... |
